Treatment potential of pathogen-reactive antibodies sequentially purified from pooled human immunoglobulin.
Antibodies, Bacterial
/ isolation & purification
Antigens, Bacterial
/ chemistry
Cell Wall
/ chemistry
Chromatography, Affinity
/ methods
Humans
Immunoglobulin Fc Fragments
/ chemistry
Immunoglobulins, Intravenous
/ chemistry
Neutrophils
/ cytology
Opsonin Proteins
/ isolation & purification
Phagocytosis
/ drug effects
Primary Cell Culture
Staphylococcus aureus
/ chemistry
Streptococcus pyogenes
/ chemistry
Vancomycin-Resistant Enterococci
/ chemistry
Antimicrobial resistance
Enterococcus
IVIG
Opsonophagocytic killing
Pooled human immunoglobulin
Staphylococcus aureus
Journal
BMC research notes
ISSN: 1756-0500
Titre abrégé: BMC Res Notes
Pays: England
ID NLM: 101462768
Informations de publication
Date de publication:
15 Apr 2019
15 Apr 2019
Historique:
received:
05
03
2019
accepted:
06
04
2019
entrez:
18
4
2019
pubmed:
18
4
2019
medline:
14
8
2019
Statut:
epublish
Résumé
Intravenous immune globulin (IVIG), pooled from human blood, is a polyspecific antibody preparation that inhibits the super-antigenic proteins associated with streptococcal and staphylococcal toxic shock, and the Shiga toxin. In addition to this toxin-neutralising activity, IVIG contains other pathogen-reactive antibodies that may confer additional therapeutic benefits. We sought to determine if pathogen-reactive antibodies that promote opsonophagocytosis of different organisms can be sequentially affinity-purified from one IVIG preparation. Antibodies that recognise cell wall antigens of Streptococcus pyogenes, Staphylococcus aureus, and vancomycin-resistant enterococcus (VRE) were sequentially affinity-purified from a single preparation of commercial IVIG and opsonophagocytic activity was assessed using a flow cytometry assay of neutrophil uptake. Non-specific IgG-binding proteins were removed from the S. aureus preparations using an immobilised Fc fragment column, produced using IVIG cleaved with the Immunoglobulin G-degrading enzyme of S. pyogenes (IdeS). Affinity-purified anti-S. aureus and anti-VRE immunoglobulin promoted significantly higher levels of opsonophagocytic uptake by human neutrophils than IVIG when identical total antibody concentrations were compared, confirming activity previously shown for affinity-purified anti-S. pyogenes immunoglobulin. The opsonophagocytic activities of anti-S. pyogenes, anti-S. aureus, and anti-VRE antibodies that were sequentially purified from a single IVIG preparation were undiminished compared to antibodies purified from previously unused IVIG.
Identifiants
pubmed: 30992057
doi: 10.1186/s13104-019-4262-8
pii: 10.1186/s13104-019-4262-8
pmc: PMC6466806
doi:
Substances chimiques
Antibodies, Bacterial
0
Antigens, Bacterial
0
Immunoglobulin Fc Fragments
0
Immunoglobulins, Intravenous
0
Opsonin Proteins
0
Types de publication
Journal Article
Langues
eng
Pagination
228Subventions
Organisme : National Institute for Health Research
ID : HPRU-2012-10047
Organisme : Medical Research Council
ID : G0800777
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_12015
Pays : United Kingdom
Organisme : Medical Research Council
ID : Confidence in Concept
Pays : United Kingdom
Organisme : United Kingdom Clinical Research Collaboration
ID : G0800777
Références
Proc Natl Acad Sci U S A. 2002 May 28;99(11):7687-92
pubmed: 12032344
Clin Diagn Lab Immunol. 2004 Nov;11(6):1158-64
pubmed: 15539522
Antimicrob Agents Chemother. 2007 Dec;51(12):4249-54
pubmed: 17893153
Autoimmun Rev. 2008 Jun;7(6):435-9
pubmed: 18558358
Curr Opin Pharmacol. 2009 Oct;9(5):552-7
pubmed: 19733119
Eur J Clin Microbiol Infect Dis. 2013 Sep;32(9):1149-60
pubmed: 23532569
Cochrane Database Syst Rev. 2013 Sep 16;(9):CD001090
pubmed: 24043371
Clin Microbiol Infect. 2014 May;20 Suppl 5:66-75
pubmed: 24476315
Infection. 2015 Apr;43(2):169-75
pubmed: 25428225
Sci Rep. 2015 Oct 28;5:15825
pubmed: 26508447
J Microbiol Methods. 2016 May;124:69-71
pubmed: 27030640
Sci Transl Med. 2016 Sep 21;8(357):357ra124
pubmed: 27655850
Infect Drug Resist. 2016 Dec 08;9:301-311
pubmed: 27994476
Microb Genom. 2016 Feb 23;2(2):e000049
pubmed: 28348843
J Pediatr. 1988 Dec;113(6):1008-14
pubmed: 3057156
Infect Immun. 1996 May;64(5):1659-65
pubmed: 8613375
Microbiology. 1998 Apr;144 ( Pt 4):985-91
pubmed: 9579072